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Health-Related Quality of Life in
Patients With Sarcoma: Enhancing
Personalized Medicine
TO THE EDITOR: We read with great interest the Special Series
entitled “Novel Therapeutic and Diagnostic Advances in Bone
and Soft Tissue Sarcomas.” These articles provide comprehensive
insight into current knowledge and evolving research in this
heterogeneous group of tumors. Although relevant diagnostic and
therapeutic aspects of patient care are considered, there is almost
no reference to the patient perspective on these advances. Most
authors acknowledge the need for individualized care, with respect
to clinical, genetic, and molecular factors; however, only Gounder
et al1 refer to health-related quality of life (HRQOL) measures as
potentially meaningful clinical end points in locally advanced
connective tissue tumors.
Historically, evaluation of oncologic treatments has focused
on objective outcomes such as radiologic response, progression-
free and overall survival, and health care provider perspectives on
treatment-related toxicities. More recently, increasing attention has
been given to patient-reported outcomes (PROs), deﬁned as “any
report of the status of a patient’s health condition that comes
directly from the patient, without interpretation of the patient’s
response by a clinician or anyone else,”2(p2) to evaluate treatment
efﬁcacy. PROs include a range of outcomes such as symptoms,
functioning, and HRQOL. HRQOL is the most widely used PRO
and is a multidimensional concept that includes the patient’s per-
ception of the impact of the disease and its treatment on physical,
psychological, and social functioning.3 Incorporating PROs into
clinical practice can facilitate communication, improve symptom
control and patient satisfaction, and reduce hospital admissions.4
A recent study in patients with metastatic solid tumors showed
that routine PRO monitoring and immediate response to adverse
events led to a 5-month survival beneﬁt compared with stan-
dard care,5 longer than that associated with most new drugs for
metastatic cancers approved by the US Food and Drug Adminis-
tration in 2016.6
Data on HRQOL in patients with sarcoma are limited; however,
many patients experience a substantial burden of physical and
psychological symptoms, with an adverse impact on HRQOL.7
Integration of HRQOL with traditional measures of therapeutic
response will provide a more comprehensive assessment of the
efﬁcacy and toxicity of novel therapies for patients with sarcoma.8
Symptomatic toxicities are frequently underreported by clini-
cians; therefore, PROs are a vital component of symptom detection,
monitoring, and early intervention.9 Precise assessments of how
patients feel and function offer important additional information in
evaluating the risks and beneﬁts of treatments.3 Patient experience is
a key aspect of drug development, and survival alone is inadequate to
determine net clinical beneﬁt.10 Although some novel treatments
have been approved for sarcomas over the last few decades, detailed
data on short- and long-term adverse effects andHRQOL are scarce.7
The PALETTE (Pazopanib for Metastatic Soft Tissue Sarcoma) study
of pazopanib versus placebo as second-line or greater treatment of
advanced soft tissue sarcomas is one of the few sarcoma trials to
report HRQOL as an exploratory end point.11 Pazopanib improved
progression-free survival without relevant deterioration in HRQOL
compared with placebo. This demonstrates that combining HRQOL
with clinical data can show overall clinical treatment beneﬁt.
One of the biggest challenges in sarcoma is how to assess
HRQOL in this heterogeneous patient group. Previous studies
have predominately used generic HRQOL instruments (European
Organisation for Research and Treatment of Cancer Quality of Life
Questionnaire Core 30, Short Form 36, Functional Assessment of
Cancer Therapy–General); however, these tools do not efﬁciently
capture the unique experiences of patients with sarcoma (eg, disease
localization, treatment-speciﬁc symptoms) and thus lack content
validity. Traditionally, inadequate content coverage has been addressed
using a tumor-speciﬁc questionnaire that captures all disease-speciﬁc
HRQOL issues, in conjunctionwith generic HRQOLmeasures. Given
the heterogeneity of sarcomas, including patient age, histologic
subtype, physiologic locations, disease stage, and rapidly changing
treatment landscape, associated with variable mechanisms of action
and toxicity proﬁles, it may be challenging to develop one sarcoma-
speciﬁc questionnaire that meets the needs of clinical practice,
academia, and industry. Standardized, so-called static, question-
naires consisting of a ﬁxed set of itemsmay not be relevant for every
patient with sarcoma and may miss important patient-reported
adverse events. Consequently, a more ﬂexible approach is needed
to assess the impact of treatments, provide optimal supportive care,
and ultimately translate into meaningful outcomes for patients with
sarcoma.12 One option is to combine standardized PRO question-
naires with validated items from item libraries (eg, Patient-Reported
Outcomes Measurement Information System, European Organisa-
tion for Research and Treatment of Cancer) to ensure adequate
assessment of speciﬁc treatments and their effects on common health
problems.12
In this era of personalized medicine, the principal focus
has been on clinical and tumor characteristics, without addressing
individual patient perspectives. If we really want to make a dif-
ference, truly provide personalized care, and conduct trials that are
attractive to patients, we should routinely involve patients in trial
design and integrate HRQOL assessments into clinical practice and
research.13 This will enable provision of a more holistic approach
in the overall management of patients.
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